To predict the pancreatic cancer patients’ response to immunotherapy, we further investigated the difference in the expression of immune checkpoints (PD-1, PD-L1, CTLA-4, LAG3, TIGIT and TIM-3) between patients with low and high m6Ascore (Fig. 9A-F). This evidence concerns the gene LAG3 and familial pancreatic carcinoma.